Home > Healthcare > Biotechnology > Biotechnology R&D > Autologous Cell Therapy Market
Autologous Cell Therapy Market Share
- Report ID: GMI6031
- Published Date: Jun 2023
- Report Format: PDF
Autologous Cell Therapy Market Share
Major companies operating in the autologous cell therapy market include
- Lonza Group AG
- Novartis AG
- Bristol-Myers Squibb Company
- Corning Incorporated
These companies majorly adopt various strategies including collaborations, acquisitions, mergers, and partnerships to create a global footprint and sustain market competition.
Frequently Asked Questions (FAQ) :
Global market for autologous cell therapy accounted for USD 12.9 billion in 2022 and will reach USD 38 billion by 2032, owing to the rising prevalence of chronic disease coupled with growing demand for personalized treatment.
The bone marrow segment is expected to register USD 16.5 billion by end of 2032, as cells sourced from bone marrow for autologous cell therapy reduces the risk of immune rejection or adverse reactions.
North America autologous cell therapy market accounted for over 42.2% revenue share in 2022 and will continue growing through 2032, backed by the presence of well-established healthcare infrastructure, key market players, and academic institutions in the region.
Lonza Group AG, Novartis AG, Bristol-Myers Squibb Company, Corning Incorporated among others.
Autologous Cell Therapy Market Scope
×
Get a free sample of
Autologous Cell Therapy Market
Inquiry Before Buying
Get special pricing options on this report
Request Sectional Data
Over 70% of our clients customize reports to fit their needs. Please tell us how you would like to customize yours
below